These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
426 related articles for article (PubMed ID: 29614779)
61. Role of humoral immunity in host defense against HIV. Baum LL Curr HIV/AIDS Rep; 2010 Feb; 7(1):11-8. PubMed ID: 20425053 [TBL] [Abstract][Full Text] [Related]
62. Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination. Cram JA; Fiore-Gartland AJ; Srinivasan S; Karuna S; Pantaleo G; Tomaras GD; Fredricks DN; Kublin JG PLoS One; 2019; 14(12):e0225622. PubMed ID: 31869338 [TBL] [Abstract][Full Text] [Related]
63. Antibodies in HIV-1 vaccine development and therapy. Klein F; Mouquet H; Dosenovic P; Scheid JF; Scharf L; Nussenzweig MC Science; 2013 Sep; 341(6151):1199-204. PubMed ID: 24031012 [TBL] [Abstract][Full Text] [Related]
64. Catch Me If You Can--The Race Between HIV and Neutralizing Antibodies. Geiß Y; Dietrich U AIDS Rev; 2015; 17(2):107-13. PubMed ID: 26035168 [TBL] [Abstract][Full Text] [Related]
66. HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development. Rao M; Peachman KK; Kim J; Gao G; Alving CR; Michael NL; Rao VB Curr HIV Res; 2013 Jul; 11(5):427-38. PubMed ID: 24191938 [TBL] [Abstract][Full Text] [Related]
67. Broadly neutralizing antibodies against HIV-1: templates for a vaccine. van Gils MJ; Sanders RW Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615 [TBL] [Abstract][Full Text] [Related]
68. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ; Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870 [TBL] [Abstract][Full Text] [Related]
69. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. Koff WC Vaccine; 2012 Jun; 30(29):4310-5. PubMed ID: 22100891 [TBL] [Abstract][Full Text] [Related]
70. Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design. McGuire AT Curr Opin HIV AIDS; 2019 Jul; 14(4):294-301. PubMed ID: 30946041 [TBL] [Abstract][Full Text] [Related]
71. Immunoprofiling Correlates of Protection Against SHIV Infection in Adjuvanted HIV-1 Pox-Protein Vaccinated Rhesus Macaques. Lu P; Guerin DJ; Lin S; Chaudhury S; Ackerman ME; Bolton DL; Wallqvist A Front Immunol; 2021; 12():625030. PubMed ID: 34046030 [TBL] [Abstract][Full Text] [Related]
72. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine. McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402 [TBL] [Abstract][Full Text] [Related]
73. The 2017 Keystone Symposium on HIV Vaccines. Cottrell CA; Ward AB Hum Vaccin Immunother; 2017 Oct; 13(10):2348-2351. PubMed ID: 28786733 [No Abstract] [Full Text] [Related]
74. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy? Subbaraman H; Schanz M; Trkola A Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627 [TBL] [Abstract][Full Text] [Related]
75. Correlations between HIV-1 clades and HIV-1 antibody neutralization sensitivity: significant for vaccine development? van Gils MJ; Schuitemaker H Curr HIV Res; 2010 Dec; 8(8):579-86. PubMed ID: 21054254 [TBL] [Abstract][Full Text] [Related]
76. HIV/AIDS: vaccines and alternate strategies for treatment and prevention. Voronin Y; Phogat S Ann N Y Acad Sci; 2010 Sep; 1205 Suppl 1():E1-9. PubMed ID: 20860672 [TBL] [Abstract][Full Text] [Related]
77. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments. Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264 [TBL] [Abstract][Full Text] [Related]
78. Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials. Huang Y; Zhang L; Janes H; Frahm N; Isaacs A; Kim JH; Montefiori D; McElrath MJ; Tomaras GD; Gilbert PB Vaccine; 2017 Feb; 35(8):1184-1193. PubMed ID: 28131393 [TBL] [Abstract][Full Text] [Related]
79. Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. Viegas EO; Kroidl A; Munseri PJ; Missanga M; Nilsson C; Tembe N; Bauer A; Joachim A; Joseph S; Mann P; Geldmacher C; Fleck S; Stöhr W; Scarlatti G; Aboud S; Bakari M; Maboko L; Hoelscher M; Wahren B; Robb ML; Weber J; McCormack S; Biberfeld G; Jani IV; Sandström E; Lyamuya E; PLoS One; 2018; 13(11):e0206838. PubMed ID: 30496299 [TBL] [Abstract][Full Text] [Related]